Baseline clinical, pathologic, and outcome data on patients in both cohorts stratified by TCA expression status
| . | TCA status . | . | |||
|---|---|---|---|---|---|
| . | Positive . | Negative . | . | ||
| . | Value . | N examined . | Value . | N examined . | P . |
| Age, median (range) | 40 (10-85) | 44 | 36 (9-87) | 191 | .53* |
| Male sex, n (%) | 22 (51) | 44 | 108 (57) | 191 | .51† |
| B-symptoms, n (%) | 10 (43) | 45 | 41 (41) | 100 | .82† |
| Ann Arbor stage, n (%) | .31† | ||||
| I/II | 23 (70) | 33 | 66 (60) | 110 | |
| III/IV | 10 (30) | 33 | 44 (40) | 110 | |
| Histology, n (%) | .002‡ | ||||
| Nodular sclerosis | 40 (80) | 50 | 156 (57.3) | 272 | |
| Mixed cellularity | 4 (8) | 50 | 88 (32.3) | 272 | |
| Lymphocyte rich | 0 (0) | 50 | 9 (3.3) | 272 | |
| Lymphocyte depleted | 1 (2) | 50 | 5 (1.8) | 272 | |
| cHL, not further subclassified | 5 (10) | 50 | 14 (5.1) | 272 | |
| Treatment (n = 26) | |||||
| Chemotherapy, ABVD | 24 (72.7)§ | 32 | 43 (44.3) | 97 | |
| Chemotherapy, COPP | 1 (3.03) | 32 | 30 (31) | 97 | |
| Other chemotherapy | 8 (24.2) | 32 | NA | ||
| Radiation only | 0 (0) | 32 | 24 (24.7) | 97 | |
| Response (n = 25) | |||||
| Complete | 18 (72) | 25 | NA | ||
| Partial | 5 (20) | 25 | NA | ||
| No | 2 (8) | 25 | NA | ||
| Outcome, n (%) | |||||
| Relapsed | 11 (35) | 32 | 37 (25.5) | 145 | .3† |
| Died | 11 (30) | 36 | 38 (26.2) | 145 | .59† |
| . | TCA status . | . | |||
|---|---|---|---|---|---|
| . | Positive . | Negative . | . | ||
| . | Value . | N examined . | Value . | N examined . | P . |
| Age, median (range) | 40 (10-85) | 44 | 36 (9-87) | 191 | .53* |
| Male sex, n (%) | 22 (51) | 44 | 108 (57) | 191 | .51† |
| B-symptoms, n (%) | 10 (43) | 45 | 41 (41) | 100 | .82† |
| Ann Arbor stage, n (%) | .31† | ||||
| I/II | 23 (70) | 33 | 66 (60) | 110 | |
| III/IV | 10 (30) | 33 | 44 (40) | 110 | |
| Histology, n (%) | .002‡ | ||||
| Nodular sclerosis | 40 (80) | 50 | 156 (57.3) | 272 | |
| Mixed cellularity | 4 (8) | 50 | 88 (32.3) | 272 | |
| Lymphocyte rich | 0 (0) | 50 | 9 (3.3) | 272 | |
| Lymphocyte depleted | 1 (2) | 50 | 5 (1.8) | 272 | |
| cHL, not further subclassified | 5 (10) | 50 | 14 (5.1) | 272 | |
| Treatment (n = 26) | |||||
| Chemotherapy, ABVD | 24 (72.7)§ | 32 | 43 (44.3) | 97 | |
| Chemotherapy, COPP | 1 (3.03) | 32 | 30 (31) | 97 | |
| Other chemotherapy | 8 (24.2) | 32 | NA | ||
| Radiation only | 0 (0) | 32 | 24 (24.7) | 97 | |
| Response (n = 25) | |||||
| Complete | 18 (72) | 25 | NA | ||
| Partial | 5 (20) | 25 | NA | ||
| No | 2 (8) | 25 | NA | ||
| Outcome, n (%) | |||||
| Relapsed | 11 (35) | 32 | 37 (25.5) | 145 | .3† |
| Died | 11 (30) | 36 | 38 (26.2) | 145 | .59† |
COPP, cyclophosphamide, vincristine, procarbazine, and prednisone; NA, data not available.
Mann-Whitney U test was used for differences in age.
χ2 was used for differences in proportions.
χ2 performed for histology dichotomized as NS and non-NS histology.
Ten patients additionally received radiotherapy; in one, bleomycin was omitted owing to pulmonary dysfunction.